オマリズマブバイオシミラーのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Omalizumab Biosimilars Market Insights, Forecast to 2028

• レポートコード：QY2207E10431 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界のオマリズマブバイオシミラーの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にオマリズマブバイオシミラーの世界市場のxxx％を占める「150 mg/mL」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「持続性喘息」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のオマリズマブバイオシミラーの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのオマリズマブバイオシミラー市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのオマリズマブバイオシミラー市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 オマリズマブバイオシミラーのグローバル主要メーカーには、Roche、Novartis、Glenmark Pharmaceuticals、Selexis、Generium、CuraTeQ、Celltrion Healthcare、Alvotech、BiosanaPharma、Mabpharm、CSPC Pharmaceutical Group、Biomabs、HisunPharm、Grand Pharmなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 オマリズマブバイオシミラー市場は、種類と用途によって区分されます。世界のオマリズマブバイオシミラー市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 150 mg/mL、75 mg/0.5 mL 【用途別セグメント】 持続性喘息、鼻ポリープ、慢性特発性蕁麻疹 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - オマリズマブバイオシミラー製品概要 - 種類別市場（150 mg/mL、75 mg/0.5 mL） - 用途別市場（持続性喘息、鼻ポリープ、慢性特発性蕁麻疹） - 調査の目的 ・エグゼクティブサマリー - 世界のオマリズマブバイオシミラー販売量予測2017-2028 - 世界のオマリズマブバイオシミラー売上予測2017-2028 - オマリズマブバイオシミラーの地域別販売量 - オマリズマブバイオシミラーの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別オマリズマブバイオシミラー販売量 - 主要メーカー別オマリズマブバイオシミラー売上 - 主要メーカー別オマリズマブバイオシミラー価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（150 mg/mL、75 mg/0.5 mL） - オマリズマブバイオシミラーの種類別販売量 - オマリズマブバイオシミラーの種類別売上 - オマリズマブバイオシミラーの種類別価格 ・用途別市場規模（持続性喘息、鼻ポリープ、慢性特発性蕁麻疹） - オマリズマブバイオシミラーの用途別販売量 - オマリズマブバイオシミラーの用途別売上 - オマリズマブバイオシミラーの用途別価格 ・北米市場 - 北米のオマリズマブバイオシミラー市場規模（種類別、用途別） - 主要国別のオマリズマブバイオシミラー市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのオマリズマブバイオシミラー市場規模（種類別、用途別） - 主要国別のオマリズマブバイオシミラー市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のオマリズマブバイオシミラー市場規模（種類別、用途別） - 主要国別のオマリズマブバイオシミラー市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のオマリズマブバイオシミラー市場規模（種類別、用途別） - 主要国別のオマリズマブバイオシミラー市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのオマリズマブバイオシミラー市場規模（種類別、用途別） - 主要国別のオマリズマブバイオシミラー市場規模（トルコ、サウジアラビア） ・企業情報 Roche、Novartis、Glenmark Pharmaceuticals、Selexis、Generium、CuraTeQ、Celltrion Healthcare、Alvotech、BiosanaPharma、Mabpharm、CSPC Pharmaceutical Group、Biomabs、HisunPharm、Grand Pharm ・産業チェーン及び販売チャネル分析 - オマリズマブバイオシミラーの産業チェーン分析 - オマリズマブバイオシミラーの原材料 - オマリズマブバイオシミラーの生産プロセス - オマリズマブバイオシミラーの販売及びマーケティング - オマリズマブバイオシミラーの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - オマリズマブバイオシミラーの産業動向 - オマリズマブバイオシミラーのマーケットドライバー - オマリズマブバイオシミラーの課題 - オマリズマブバイオシミラーの阻害要因 ・主な調査結果

Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Market Analysis and Insights: Global Omalizumab Biosimilars Market
Due to the COVID-19 pandemic, the global Omalizumab Biosimilars market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, 150 mg/mL accounting for % of the Omalizumab Biosimilars global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Persistent Asthma segment is altered to an % CAGR throughout this forecast period.
China Omalizumab Biosimilars market size is valued at US$ million in 2021, while the US and Europe Omalizumab Biosimilars are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Omalizumab Biosimilars landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Omalizumab Biosimilars include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech and BiosanaPharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Omalizumab Biosimilars Scope and Segment
Omalizumab Biosimilars market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Omalizumab Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
150 mg/mL
75 mg/0.5 mL
Segment by Application
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
By Company
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Grand Pharm
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Omalizumab Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Omalizumab Biosimilars Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Market by Application
1.3.1 Global Omalizumab Biosimilars Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Persistent Asthma
1.3.3 Nasal Polyps
1.3.4 Chronic Idiopathic Urticaria
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Omalizumab Biosimilars Sales Estimates and Forecasts 2017-2028
2.2 Global Omalizumab Biosimilars Revenue Estimates and Forecasts 2017-2028
2.3 Global Omalizumab Biosimilars Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Omalizumab Biosimilars Sales by Region
2.4.1 Global Omalizumab Biosimilars Sales by Region (2017-2022)
2.4.2 Global Sales Omalizumab Biosimilars by Region (2023-2028)
2.5 Global Omalizumab Biosimilars Revenue by Region
2.5.1 Global Omalizumab Biosimilars Revenue by Region (2017-2022)
2.5.2 Global Omalizumab Biosimilars Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Omalizumab Biosimilars Sales by Manufacturers
3.1.1 Global Top Omalizumab Biosimilars Manufacturers by Sales (2017-2022)
3.1.2 Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Omalizumab Biosimilars in 2021
3.2 Global Omalizumab Biosimilars Revenue by Manufacturers
3.2.1 Global Omalizumab Biosimilars Revenue by Manufacturers (2017-2022)
3.2.2 Global Omalizumab Biosimilars Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Omalizumab Biosimilars Revenue in 2021
3.3 Global Omalizumab Biosimilars Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Omalizumab Biosimilars Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Omalizumab Biosimilars Sales by Type
4.1.1 Global Omalizumab Biosimilars Historical Sales by Type (2017-2022)
4.1.2 Global Omalizumab Biosimilars Forecasted Sales by Type (2023-2028)
4.1.3 Global Omalizumab Biosimilars Sales Market Share by Type (2017-2028)
4.2 Global Omalizumab Biosimilars Revenue by Type
4.2.1 Global Omalizumab Biosimilars Historical Revenue by Type (2017-2022)
4.2.2 Global Omalizumab Biosimilars Forecasted Revenue by Type (2023-2028)
4.2.3 Global Omalizumab Biosimilars Revenue Market Share by Type (2017-2028)
4.3 Global Omalizumab Biosimilars Price by Type
4.3.1 Global Omalizumab Biosimilars Price by Type (2017-2022)
4.3.2 Global Omalizumab Biosimilars Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Omalizumab Biosimilars Sales by Application
5.1.1 Global Omalizumab Biosimilars Historical Sales by Application (2017-2022)
5.1.2 Global Omalizumab Biosimilars Forecasted Sales by Application (2023-2028)
5.1.3 Global Omalizumab Biosimilars Sales Market Share by Application (2017-2028)
5.2 Global Omalizumab Biosimilars Revenue by Application
5.2.1 Global Omalizumab Biosimilars Historical Revenue by Application (2017-2022)
5.2.2 Global Omalizumab Biosimilars Forecasted Revenue by Application (2023-2028)
5.2.3 Global Omalizumab Biosimilars Revenue Market Share by Application (2017-2028)
5.3 Global Omalizumab Biosimilars Price by Application
5.3.1 Global Omalizumab Biosimilars Price by Application (2017-2022)
5.3.2 Global Omalizumab Biosimilars Price Forecast by Application (2023-2028)
6 North America
6.1 North America Omalizumab Biosimilars Market Size by Type
6.1.1 North America Omalizumab Biosimilars Sales by Type (2017-2028)
6.1.2 North America Omalizumab Biosimilars Revenue by Type (2017-2028)
6.2 North America Omalizumab Biosimilars Market Size by Application
6.2.1 North America Omalizumab Biosimilars Sales by Application (2017-2028)
6.2.2 North America Omalizumab Biosimilars Revenue by Application (2017-2028)
6.3 North America Omalizumab Biosimilars Market Size by Country
6.3.1 North America Omalizumab Biosimilars Sales by Country (2017-2028)
6.3.2 North America Omalizumab Biosimilars Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Omalizumab Biosimilars Market Size by Type
7.1.1 Europe Omalizumab Biosimilars Sales by Type (2017-2028)
7.1.2 Europe Omalizumab Biosimilars Revenue by Type (2017-2028)
7.2 Europe Omalizumab Biosimilars Market Size by Application
7.2.1 Europe Omalizumab Biosimilars Sales by Application (2017-2028)
7.2.2 Europe Omalizumab Biosimilars Revenue by Application (2017-2028)
7.3 Europe Omalizumab Biosimilars Market Size by Country
7.3.1 Europe Omalizumab Biosimilars Sales by Country (2017-2028)
7.3.2 Europe Omalizumab Biosimilars Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Omalizumab Biosimilars Market Size by Type
8.1.1 Asia Pacific Omalizumab Biosimilars Sales by Type (2017-2028)
8.1.2 Asia Pacific Omalizumab Biosimilars Revenue by Type (2017-2028)
8.2 Asia Pacific Omalizumab Biosimilars Market Size by Application
8.2.1 Asia Pacific Omalizumab Biosimilars Sales by Application (2017-2028)
8.2.2 Asia Pacific Omalizumab Biosimilars Revenue by Application (2017-2028)
8.3 Asia Pacific Omalizumab Biosimilars Market Size by Region
8.3.1 Asia Pacific Omalizumab Biosimilars Sales by Region (2017-2028)
8.3.2 Asia Pacific Omalizumab Biosimilars Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Omalizumab Biosimilars Market Size by Type
9.1.1 Latin America Omalizumab Biosimilars Sales by Type (2017-2028)
9.1.2 Latin America Omalizumab Biosimilars Revenue by Type (2017-2028)
9.2 Latin America Omalizumab Biosimilars Market Size by Application
9.2.1 Latin America Omalizumab Biosimilars Sales by Application (2017-2028)
9.2.2 Latin America Omalizumab Biosimilars Revenue by Application (2017-2028)
9.3 Latin America Omalizumab Biosimilars Market Size by Country
9.3.1 Latin America Omalizumab Biosimilars Sales by Country (2017-2028)
9.3.2 Latin America Omalizumab Biosimilars Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Omalizumab Biosimilars Market Size by Type
10.1.1 Middle East and Africa Omalizumab Biosimilars Sales by Type (2017-2028)
10.1.2 Middle East and Africa Omalizumab Biosimilars Revenue by Type (2017-2028)
10.2 Middle East and Africa Omalizumab Biosimilars Market Size by Application
10.2.1 Middle East and Africa Omalizumab Biosimilars Sales by Application (2017-2028)
10.2.2 Middle East and Africa Omalizumab Biosimilars Revenue by Application (2017-2028)
10.3 Middle East and Africa Omalizumab Biosimilars Market Size by Country
10.3.1 Middle East and Africa Omalizumab Biosimilars Sales by Country (2017-2028)
10.3.2 Middle East and Africa Omalizumab Biosimilars Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Overview
11.1.3 Roche Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Roche Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Roche Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Overview
11.2.3 Novartis Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Novartis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Novartis Recent Developments
11.3 Glenmark Pharmaceuticals
11.3.1 Glenmark Pharmaceuticals Corporation Information
11.3.2 Glenmark Pharmaceuticals Overview
11.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Glenmark Pharmaceuticals Recent Developments
11.4 Selexis
11.4.1 Selexis Corporation Information
11.4.2 Selexis Overview
11.4.3 Selexis Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Selexis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Selexis Recent Developments
11.5 Generium
11.5.1 Generium Corporation Information
11.5.2 Generium Overview
11.5.3 Generium Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Generium Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Generium Recent Developments
11.6 CuraTeQ
11.6.1 CuraTeQ Corporation Information
11.6.2 CuraTeQ Overview
11.6.3 CuraTeQ Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 CuraTeQ Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 CuraTeQ Recent Developments
11.7 Celltrion Healthcare
11.7.1 Celltrion Healthcare Corporation Information
11.7.2 Celltrion Healthcare Overview
11.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Celltrion Healthcare Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Celltrion Healthcare Recent Developments
11.8 Alvotech
11.8.1 Alvotech Corporation Information
11.8.2 Alvotech Overview
11.8.3 Alvotech Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Alvotech Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Alvotech Recent Developments
11.9 BiosanaPharma
11.9.1 BiosanaPharma Corporation Information
11.9.2 BiosanaPharma Overview
11.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 BiosanaPharma Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 BiosanaPharma Recent Developments
11.10 Mabpharm
11.10.1 Mabpharm Corporation Information
11.10.2 Mabpharm Overview
11.10.3 Mabpharm Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Mabpharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Mabpharm Recent Developments
11.11 CSPC Pharmaceutical Group
11.11.1 CSPC Pharmaceutical Group Corporation Information
11.11.2 CSPC Pharmaceutical Group Overview
11.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 CSPC Pharmaceutical Group Recent Developments
11.12 Biomabs
11.12.1 Biomabs Corporation Information
11.12.2 Biomabs Overview
11.12.3 Biomabs Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Biomabs Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Biomabs Recent Developments
11.13 HisunPharm
11.13.1 HisunPharm Corporation Information
11.13.2 HisunPharm Overview
11.13.3 HisunPharm Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 HisunPharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 HisunPharm Recent Developments
11.14 Grand Pharm
11.14.1 Grand Pharm Corporation Information
11.14.2 Grand Pharm Overview
11.14.3 Grand Pharm Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Grand Pharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Grand Pharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Omalizumab Biosimilars Industry Chain Analysis
12.2 Omalizumab Biosimilars Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Omalizumab Biosimilars Production Mode & Process
12.4 Omalizumab Biosimilars Sales and Marketing
12.4.1 Omalizumab Biosimilars Sales Channels
12.4.2 Omalizumab Biosimilars Distributors
12.5 Omalizumab Biosimilars Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Omalizumab Biosimilars Industry Trends
13.2 Omalizumab Biosimilars Market Drivers
13.3 Omalizumab Biosimilars Market Challenges
13.4 Omalizumab Biosimilars Market Restraints
14 Key Findings in The Global Omalizumab Biosimilars Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Omalizumab Biosimilars Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 150 mg/mL
Table 3. Major Manufacturers of 75 mg/0.5 mL
Table 4. Global Omalizumab Biosimilars Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Omalizumab Biosimilars Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Omalizumab Biosimilars Sales by Region (2017-2022) & (Units)
Table 7. Global Omalizumab Biosimilars Sales Market Share by Region (2017-2022)
Table 8. Global Omalizumab Biosimilars Sales by Region (2023-2028) & (Units)
Table 9. Global Omalizumab Biosimilars Sales Market Share by Region (2023-2028)
Table 10. Global Omalizumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Omalizumab Biosimilars Revenue Market Share by Region (2017-2022)
Table 12. Global Omalizumab Biosimilars Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Omalizumab Biosimilars Revenue Market Share by Region (2023-2028)
Table 14. Global Omalizumab Biosimilars Sales by Manufacturers (2017-2022) & (Units)
Table 15. Global Omalizumab Biosimilars Sales Share by Manufacturers (2017-2022)
Table 16. Global Omalizumab Biosimilars Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Omalizumab Biosimilars Revenue Share by Manufacturers (2017-2022)
Table 18. Omalizumab Biosimilars Price by Manufacturers (2017-2022) &(K USD/Unit)
Table 19. Global Omalizumab Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Omalizumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Biosimilars as of 2021)
Table 21. Omalizumab Biosimilars Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Omalizumab Biosimilars Product Offered
Table 23. Date of Manufacturers Enter into Omalizumab Biosimilars Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Omalizumab Biosimilars Sales by Type (2017-2022) & (Units)
Table 26. Global Omalizumab Biosimilars Sales by Type (2023-2028) & (Units)
Table 27. Global Omalizumab Biosimilars Sales Share by Type (2017-2022)
Table 28. Global Omalizumab Biosimilars Sales Share by Type (2023-2028)
Table 29. Global Omalizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Omalizumab Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Omalizumab Biosimilars Revenue Share by Type (2017-2022)
Table 32. Global Omalizumab Biosimilars Revenue Share by Type (2023-2028)
Table 33. Omalizumab Biosimilars Price by Type (2017-2022) & (K USD/Unit)
Table 34. Global Omalizumab Biosimilars Price Forecast by Type (2023-2028) & (K USD/Unit)
Table 35. Global Omalizumab Biosimilars Sales by Application (2017-2022) & (Units)
Table 36. Global Omalizumab Biosimilars Sales by Application (2023-2028) & (Units)
Table 37. Global Omalizumab Biosimilars Sales Share by Application (2017-2022)
Table 38. Global Omalizumab Biosimilars Sales Share by Application (2023-2028)
Table 39. Global Omalizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Omalizumab Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Omalizumab Biosimilars Revenue Share by Application (2017-2022)
Table 42. Global Omalizumab Biosimilars Revenue Share by Application (2023-2028)
Table 43. Omalizumab Biosimilars Price by Application (2017-2022) & (K USD/Unit)
Table 44. Global Omalizumab Biosimilars Price Forecast by Application (2023-2028) & (K USD/Unit)
Table 45. North America Omalizumab Biosimilars Sales by Type (2017-2022) & (Units)
Table 46. North America Omalizumab Biosimilars Sales by Type (2023-2028) & (Units)
Table 47. North America Omalizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Omalizumab Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Omalizumab Biosimilars Sales by Application (2017-2022) & (Units)
Table 50. North America Omalizumab Biosimilars Sales by Application (2023-2028) & (Units)
Table 51. North America Omalizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Omalizumab Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 54. North America Omalizumab Biosimilars Sales by Country (2023-2028) & (Units)
Table 55. North America Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Omalizumab Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Omalizumab Biosimilars Sales by Type (2017-2022) & (Units)
Table 58. Europe Omalizumab Biosimilars Sales by Type (2023-2028) & (Units)
Table 59. Europe Omalizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Omalizumab Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Omalizumab Biosimilars Sales by Application (2017-2022) & (Units)
Table 62. Europe Omalizumab Biosimilars Sales by Application (2023-2028) & (Units)
Table 63. Europe Omalizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Omalizumab Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 66. Europe Omalizumab Biosimilars Sales by Country (2023-2028) & (Units)
Table 67. Europe Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Omalizumab Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Omalizumab Biosimilars Sales by Type (2017-2022) & (Units)
Table 70. Asia Pacific Omalizumab Biosimilars Sales by Type (2023-2028) & (Units)
Table 71. Asia Pacific Omalizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Omalizumab Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Omalizumab Biosimilars Sales by Application (2017-2022) & (Units)
Table 74. Asia Pacific Omalizumab Biosimilars Sales by Application (2023-2028) & (Units)
Table 75. Asia Pacific Omalizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Omalizumab Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Omalizumab Biosimilars Sales by Region (2017-2022) & (Units)
Table 78. Asia Pacific Omalizumab Biosimilars Sales by Region (2023-2028) & (Units)
Table 79. Asia Pacific Omalizumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Omalizumab Biosimilars Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Omalizumab Biosimilars Sales by Type (2017-2022) & (Units)
Table 82. Latin America Omalizumab Biosimilars Sales by Type (2023-2028) & (Units)
Table 83. Latin America Omalizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Omalizumab Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Omalizumab Biosimilars Sales by Application (2017-2022) & (Units)
Table 86. Latin America Omalizumab Biosimilars Sales by Application (2023-2028) & (Units)
Table 87. Latin America Omalizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Omalizumab Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 90. Latin America Omalizumab Biosimilars Sales by Country (2023-2028) & (Units)
Table 91. Latin America Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Omalizumab Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Omalizumab Biosimilars Sales by Type (2017-2022) & (Units)
Table 94. Middle East and Africa Omalizumab Biosimilars Sales by Type (2023-2028) & (Units)
Table 95. Middle East and Africa Omalizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Omalizumab Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Omalizumab Biosimilars Sales by Application (2017-2022) & (Units)
Table 98. Middle East and Africa Omalizumab Biosimilars Sales by Application (2023-2028) & (Units)
Table 99. Middle East and Africa Omalizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Omalizumab Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 102. Middle East and Africa Omalizumab Biosimilars Sales by Country (2023-2028) & (Units)
Table 103. Middle East and Africa Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Omalizumab Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 105. Roche Corporation Information
Table 106. Roche Description and Major Businesses
Table 107. Roche Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 108. Roche Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Roche Recent Developments
Table 110. Novartis Corporation Information
Table 111. Novartis Description and Major Businesses
Table 112. Novartis Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 113. Novartis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Novartis Recent Developments
Table 115. Glenmark Pharmaceuticals Corporation Information
Table 116. Glenmark Pharmaceuticals Description and Major Businesses
Table 117. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 118. Glenmark Pharmaceuticals Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Glenmark Pharmaceuticals Recent Developments
Table 120. Selexis Corporation Information
Table 121. Selexis Description and Major Businesses
Table 122. Selexis Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 123. Selexis Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Selexis Recent Developments
Table 125. Generium Corporation Information
Table 126. Generium Description and Major Businesses
Table 127. Generium Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 128. Generium Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Generium Recent Developments
Table 130. CuraTeQ Corporation Information
Table 131. CuraTeQ Description and Major Businesses
Table 132. CuraTeQ Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 133. CuraTeQ Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. CuraTeQ Recent Developments
Table 135. Celltrion Healthcare Corporation Information
Table 136. Celltrion Healthcare Description and Major Businesses
Table 137. Celltrion Healthcare Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 138. Celltrion Healthcare Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Celltrion Healthcare Recent Developments
Table 140. Alvotech Corporation Information
Table 141. Alvotech Description and Major Businesses
Table 142. Alvotech Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 143. Alvotech Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Alvotech Recent Developments
Table 145. BiosanaPharma Corporation Information
Table 146. BiosanaPharma Description and Major Businesses
Table 147. BiosanaPharma Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 148. BiosanaPharma Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. BiosanaPharma Recent Developments
Table 150. Mabpharm Corporation Information
Table 151. Mabpharm Description and Major Businesses
Table 152. Mabpharm Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 153. Mabpharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Mabpharm Recent Developments
Table 155. CSPC Pharmaceutical Group Corporation Information
Table 156. CSPC Pharmaceutical Group Description and Major Businesses
Table 157. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 158. CSPC Pharmaceutical Group Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. CSPC Pharmaceutical Group Recent Developments
Table 160. Biomabs Corporation Information
Table 161. Biomabs Description and Major Businesses
Table 162. Biomabs Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 163. Biomabs Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. Biomabs Recent Developments
Table 165. HisunPharm Corporation Information
Table 166. HisunPharm Description and Major Businesses
Table 167. HisunPharm Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 168. HisunPharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 169. HisunPharm Recent Developments
Table 170. Grand Pharm Corporation Information
Table 171. Grand Pharm Description and Major Businesses
Table 172. Grand Pharm Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 173. Grand Pharm Omalizumab Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 174. Grand Pharm Recent Developments
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Omalizumab Biosimilars Distributors List
Table 178. Omalizumab Biosimilars Customers List
Table 179. Omalizumab Biosimilars Market Trends
Table 180. Omalizumab Biosimilars Market Drivers
Table 181. Omalizumab Biosimilars Market Challenges
Table 182. Omalizumab Biosimilars Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Omalizumab Biosimilars Product Picture
Figure 3. Global Omalizumab Biosimilars Market Share by Type in 2021 & 2028
Figure 3. 150 mg/mL Product Picture
Figure 4. 75 mg/0.5 mL Product Picture
Figure 5. Global Omalizumab Biosimilars Market Share by Application in 2021 & 2028
Figure 6. Persistent Asthma
Figure 7. Nasal Polyps
Figure 8. Chronic Idiopathic Urticaria
Figure 9. Omalizumab Biosimilars Report Years Considered
Figure 10. Global Omalizumab Biosimilars Sales 2017-2028 (Units)
Figure 11. Global Omalizumab Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Omalizumab Biosimilars Revenue 2017-2028 (US$ Million)
Figure 13. Global Omalizumab Biosimilars Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 14. Global Omalizumab Biosimilars Sales Market Share by Region (2017-2022)
Figure 15. Global Omalizumab Biosimilars Sales Market Share by Region (2023-2028)
Figure 16. North America Omalizumab Biosimilars Sales YoY (2017-2028) & (Units)
Figure 17. North America Omalizumab Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 18. Europe Omalizumab Biosimilars Sales YoY (2017-2028) & (Units)
Figure 19. Europe Omalizumab Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Asia-Pacific Omalizumab Biosimilars Sales YoY (2017-2028) & (Units)
Figure 21. Asia-Pacific Omalizumab Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Latin America Omalizumab Biosimilars Sales YoY (2017-2028) & (Units)
Figure 23. Latin America Omalizumab Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Middle East & Africa Omalizumab Biosimilars Sales YoY (2017-2028) & (Units)
Figure 25. Middle East & Africa Omalizumab Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 26. The Omalizumab Biosimilars Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 27. The Top 5 and 10 Largest Manufacturers of Omalizumab Biosimilars in the World: Market Share by Omalizumab Biosimilars Revenue in 2021
Figure 28. Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 29. Global Omalizumab Biosimilars Sales Market Share by Type (2017-2028)
Figure 30. Global Omalizumab Biosimilars Revenue Market Share by Type (2017-2028)
Figure 31. Global Omalizumab Biosimilars Sales Market Share by Application (2017-2028)
Figure 32. Global Omalizumab Biosimilars Revenue Market Share by Application (2017-2028)
Figure 33. North America Omalizumab Biosimilars Sales Market Share by Type (2017-2028)
Figure 34. North America Omalizumab Biosimilars Revenue Market Share by Type (2017-2028)
Figure 35. North America Omalizumab Biosimilars Sales Market Share by Application (2017-2028)
Figure 36. North America Omalizumab Biosimilars Revenue Market Share by Application (2017-2028)
Figure 37. North America Omalizumab Biosimilars Sales Share by Country (2017-2028)
Figure 38. North America Omalizumab Biosimilars Revenue Share by Country (2017-2028)
Figure 39. United States Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 40. Canada Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 41. Europe Omalizumab Biosimilars Sales Market Share by Type (2017-2028)
Figure 42. Europe Omalizumab Biosimilars Revenue Market Share by Type (2017-2028)
Figure 43. Europe Omalizumab Biosimilars Sales Market Share by Application (2017-2028)
Figure 44. Europe Omalizumab Biosimilars Revenue Market Share by Application (2017-2028)
Figure 45. Europe Omalizumab Biosimilars Sales Share by Country (2017-2028)
Figure 46. Europe Omalizumab Biosimilars Revenue Share by Country (2017-2028)
Figure 47. Germany Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 48. France Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 49. U.K. Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 50. Italy Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 51. Russia Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 52. Asia Pacific Omalizumab Biosimilars Sales Market Share by Type (2017-2028)
Figure 53. Asia Pacific Omalizumab Biosimilars Revenue Market Share by Type (2017-2028)
Figure 54. Asia Pacific Omalizumab Biosimilars Sales Market Share by Application (2017-2028)
Figure 55. Asia Pacific Omalizumab Biosimilars Revenue Market Share by Application (2017-2028)
Figure 56. Asia Pacific Omalizumab Biosimilars Sales Share by Region (2017-2028)
Figure 57. Asia Pacific Omalizumab Biosimilars Revenue Share by Region (2017-2028)
Figure 58. China Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 59. Japan Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 60. South Korea Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 61. India Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 62. Australia Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 63. China Taiwan Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 64. Indonesia Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 65. Thailand Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 66. Malaysia Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Omalizumab Biosimilars Sales Market Share by Type (2017-2028)
Figure 68. Latin America Omalizumab Biosimilars Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Omalizumab Biosimilars Sales Market Share by Application (2017-2028)
Figure 70. Latin America Omalizumab Biosimilars Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Omalizumab Biosimilars Sales Share by Country (2017-2028)
Figure 72. Latin America Omalizumab Biosimilars Revenue Share by Country (2017-2028)
Figure 73. Mexico Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Omalizumab Biosimilars Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Omalizumab Biosimilars Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Omalizumab Biosimilars Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Omalizumab Biosimilars Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Omalizumab Biosimilars Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Omalizumab Biosimilars Revenue Share by Country (2017-2028)
Figure 82. Turkey Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 84. UAE Omalizumab Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 85. Omalizumab Biosimilars Value Chain
Figure 86. Omalizumab Biosimilars Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

---